BioWorld MedTech

April 2, 2012

Corindus meets primary endpoints for PRECISE trial

Corindus Vascular Robotics (Natick, Massachusetts) reported it has met the primary endpoints for its PRECISE trial and results indicate the Corpath 200 System could be considered as a safer alternative to manual PCI. Read More

Trust thy lender, but pay heed to thine term sheet

Report from Europe: Abbott gains CE mark for PLEX-ID System

Washington roundup: NHS wants multi-disciplinary team for aortic valve implants

Deals roundup: HeartWare to acquire WorldHeart for $8M

MDD's Fun Facts

Financings roundup: HIT Application Solutions secures $2.75M for Notifi

HIT roundup: Lovelace selects ZeOmega Jive for integrated care

Agreements/contracts: Accuray in collaboration pact with U. of Heidelberg

Restructuring roundup: HR to lay off 3% of workforce to deal with med-device tax

Product Briefs

St. Jude pulls Brio DBS off European market

MDD's Neurology Extra

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

Roche reports new TREM2 agonists

BioWorld Science

F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...

Genescience presents STAT6 degrader for atopic dermatitis

BioWorld Science

Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....

Unmasking the X: EPAC2 shifts the fragile X landscape

BioWorld

Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...